within Pharmacolibrary.Drugs.B_BloodAndBloodFormingOrgans.B01A_AntithromboticAgents.B01AC21_Treprostinil;

model Treprostinil
  extends Pharmacolibrary.Drugs.ATC.B.B01AC21;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>B01AC21</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Treprostinil is a stable, synthetic analog of prostacyclin (PGI2) used primarily for the treatment of pulmonary arterial hypertension (PAH) to improve exercise capacity. It acts as a vasodilator of pulmonary and systemic arterial vascular beds and inhibits platelet aggregation. It is approved for use in several countries and can be administered intravenously, subcutaneously, orally, or by inhalation.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers after intravenous administration.</p><h4>References</h4><ol><li><p>Hall, K, et al., &amp; Feinstein, JA (2019). Subcutaneous and Intravenous Treprostinil Pharmacokinetics in Children With Pulmonary Vascular Disease. <i>Journal of cardiovascular pharmacology</i> 73(6) 383–393. DOI:<a href=\"https://doi.org/10.1097/FJC.0000000000000674\">10.1097/FJC.0000000000000674</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/31162247/\">https://pubmed.ncbi.nlm.nih.gov/31162247</a></p></li><li><p>Kumar, P, et al., &amp; Nelsen, A (2016). A Comprehensive Review of Treprostinil Pharmacokinetics via Four Routes of Administration. <i>Clinical pharmacokinetics</i> 55(12) 1495–1505. DOI:<a href=\"https://doi.org/10.1007/s40262-016-0409-0\">10.1007/s40262-016-0409-0</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/27286723/\">https://pubmed.ncbi.nlm.nih.gov/27286723</a></p></li><li><p>Perez, VC, et al., &amp; Rahaghi, FF (2024). Escalating Oral Treprostinil Dose With Intravenous Treprostinil Bridging Therapy. <i>Cureus</i> 16(2) e54184–None. DOI:<a href=\"https://doi.org/10.7759/cureus.54184\">10.7759/cureus.54184</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/38500893/\">https://pubmed.ncbi.nlm.nih.gov/38500893</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Treprostinil;
